Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.58 |
| ▸ | CALCA | P06881 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799385 | 1.00 | CYP3A4 (0.58) | CYP3A4CALCRLCALCA | |
| SCHEMBL5660417 | 1.00 | CYP3A4 (0.58) | CYP3A4CALCRLCALCA | |
| SCHEMBL5658602 | 0.96 | CALCA (0.56) | CYP3A4CALCRLCALCA | |
| SCHEMBL5661665 | 0.96 | CALCRL (0.56) | CYP3A4CALCRLCALCA | |
| Trifluoroacetic Acid SCHEMBL31430917 | 0.94 | CYP3A4 (0.53) | CYP3A4CALCRLCALCA | |
| Trifluoroacetic Acid SCHEMBL31180093 | 0.94 | CYP3A4 (0.53) | CYP3A4CALCRLCALCA | |
| SCHEMBL5658251 | 0.93 | CALCA (0.56) | CYP3A4CALCRLCALCA | |
| SCHEMBL3605516 | 0.92 | CALCRL (0.57) | CALCRLCALCA | |
| SCHEMBL5660491 | 0.91 | CALCA (0.53) | CALCRLCALCA | |
| SCHEMBL4862077 | 0.90 | CYP3A4 (0.48) | CYP3A4CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551081-A | New preparation method of migraine therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-13 | — | — | CN | claimed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| CN-119306709-A | Synthesis method of compound containing oxo-pyrido alicyclic heterocycle or alicyclic structure and novel intermediate | 成都思倍博医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024046223-A1 | INDAZOLE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | 熙源安健医药（上海）有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-117624191-A | Indazole carboxamide derivatives, preparation method and application thereof | 熙源安健医药（上海）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117551081-A | New preparation method of migraine therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112888438-A | Prodrugs of CGRP antagonists | 拜尔哈文制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | CYP3A4 1440/4885CALCRL 1/4885CALCA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.